Merck & Co.
AWARDS
NEWS
The FDA has three high-profile events this week, including one target action date and two advisory committee meetings—one to discuss potential traditional approval for Alzheimer’s drug Leqembi.
The company will present data at the oncology meeting showing the drug’s significant survival benefit in patients with advanced renal cancer and recurrent, persistent and metastatic cervical cancer.
Merck and AstraZeneca are seeking broad approval for Lynparza in mCRPC regardless of BRCA status.
Cancer vaccines enjoyed a moment in the spotlight this week as Moderna, Merck, Nykode Therapeutics and Transgene shared promising updates at AACR and beyond.
Moderna claims it can have vaccines ready for multiple cancer types by 2030, but experts say challenges remain.
The checkpoint inhibitor improved patient outcomes in three cancer trials, according to results presented at the AACR meeting.
JOBS
IN THE PRESS